EMA expands public tracking of medicines under CHMP review
The European Medicines Agency has updated its public catalogue of medicines for human use under evaluation, giving a month-by-month view of products moving through the Committee for Medicinal Products for Human Use review pathway. The page functions as a live procedural register for medicines seeking a European Union marketing authorisation through the centralised procedure, and it now carries more detail than before on the regulatory status of each application.
The monthly lists are not clinical trial readouts, but they do reveal the regulatory tempo behind medicines that may eventually reach prescribers and patients across Europe. Each entry includes the international non-proprietary name, or the common name for vaccines, along with a brief therapeutic indication. The INN format is deliberately stripped down to the active moiety, leaving salt, ester, or derivative information out of the listing. For clinicians and drug developers, that keeps the focus on the core product under review rather than the chemistry of the finished presentation.
Procedure timing is central to the way the agency presents the material. The CHMP meets once a month, and its scientific opinion forms the basis for authorisation decisions in the European Union. The start dates shown on the list follow the procedural timetable, although the agency notes that there are typically no start dates in April because there is no CHMP meeting in August. In practical terms, the page is a rolling record of where each dossier sits in the review queue, not a snapshot frozen in time.
A second layer of detail arrived with the 2025 and 2026 reporting changes. As of January 2025, monthly reports of applications for new human medicines under CHMP evaluation include a summary of the therapeutic indication applied for by the applicant and the date on which the procedure restarted after responses to the list of questions. That restart date matters because it marks the point at which the scientific clock begins running again after applicant clarifications have been submitted.
As of March 2025, EMA also began publishing information in Excel format on the start of procedures for extension applications and for type II variations that propose an extension of an authorised indication handled in IRIS. The agency explicitly links that shift to the transition of post-authorisation regulatory procedures into IRIS and to the wider digitalisation of EMA activity. For analysts tracking regulatory throughput, the Excel format also makes the data easier to sort and filter.
The latest monthly entries show how broad that pipeline has become.
From October 2025, three additional fields were added: “EMA prod. number,” “Is PRIME,” and “Is OPEN.” Those fields give a more granular view of the product and its regulatory pathway, including whether a medicine has been handled under the PRIME scheme. By the time the October 2026 list is posted, the registry already reflects that richer structure.
From indication extensions to first-in-line applications
The archive reaches back to 2012, giving regulators, companies, and observers a long historical record of the CHMP evaluation process. The current page includes both applications for new human medicines and procedure-start notices for extension of marketing authorisation and type II variation requests seeking an extension of indication. Those distinctions matter because they separate first-time reviews from efforts to widen the use of an already authorised product.
Several linked entries illustrate the cadence of the system across 2025 and 2026. Applications for new human medicines under evaluation are listed for January through October 2026, with separate start-of-procedure notices for extension applications and type II variations spanning late 2025 into 2026. The page also shows first publication dates for each Excel file, reinforcing its role as a procedural archive rather than a static summary.
One sentence captures the operational core of the register: the CHMP’s independent recommendations are based on a comprehensive scientific evaluation of data. That is the point at which a product moves from dossier to decision-making, with the committee’s opinion serving as the formal scientific gatekeeper for the European Union authorisation pathway.
For manufacturers, the monthly list offers a transparent marker of regulatory progress. For clinicians, it provides an early signal that a medicine is moving through Europe’s centralised review process, even if the underlying efficacy and safety data remain unpublished on this page. For policy observers, the expanded fields and Excel downloads show an agency trying to make its review system more searchable and more legible without changing the underlying scientific standard.
The register is also explicit about what it is not. It does not present trial endpoints, comparative efficacy results, or safety outcomes. It records where a medicine sits in the authorisation pipeline and how that file is being handled by CHMP. The next critical step remains the committee’s recommendation itself, followed by the downstream authorisation decision for the European market.
For now, the practical value lies in the completeness of the procedural trail. Monthly updates, archived going back more than a decade, now sit alongside added fields for product identification and regulatory pathway status, giving a clearer picture of how candidate medicines advance through European review. What the list cannot answer is whether any individual product will ultimately clear the scientific bar set by CHMP, and that judgment will depend on the full data package behind each application.